Abstract: The present invention relates to the preparation of a medicinal agent comprising DNAzymes according to Seq. ID 2-62 for the prophylaxis and treatment of virus infections that are caused by picornaviruses, in particular by rhinoviruses, in particular for the prophylaxis and treatment of rhinitis, head colds, asthma, COPD and viral infections of the upper respiratory tract.

Abstract: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.

Abstract: The present invention relates to a method for producing of a cell and/or tissue and/or disease phase specific medicament against against chronic inflammatory diseases. Disease, cell type, tissue and/or stage specific proteins and nucleic acids are identified with regard to their modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and autoimmune diseases is provided.

Abstract: A process for the preparation of a non-viable probiotic composition having anti-allergic (i.e. allergy preventive and/or anti-allergic in a therapeutic sense) properties, the process including the steps of (a) subjecting LGG to cultivation in a suitable culture medium using a batch process; (b) harvesting the culture supernatant at a late exponential phase of the cultivation step; (c) removing liquid contents from the culture supernatant so as to obtain the composition. Also, a composition comprising a proteinaceous mixture, said composition being obtainable by the above process, and the use thereof in a dietetic product preferably for targeting expecting mother's, infants, or children as well as application in food for specific medical purposes.

Abstract: A DNAzyme is disclosed, which comprises: (i) a catalytic domain with a nucleotide sequence GGCTAGCTACAACGA or a modified sequence of comparable biological effect, which cleaves T-bet mRNA at every purine-pyrimidine binding site to which it is bound; (ii) a right substrate binding domain which is contiguous with the 3?-end of the catalytic domain; and (iii) a left substrate binding domain which is contiguous with the 5?-end of the catalytic domain, whereby the two substrate binding domains are respectively complementary to two regions of the T-bet mRNA so that they hybridize with the mRNA; are active in vivo; and contain the sequences td 69 GGCAATGAA GGC TAGCTACAACGA TGGGTTTCT or td70 TCACGGCAA GGCTAGCTACAACGA GAACTGGGT.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The invention relates to a method for the production of a cell and/or tissue and/or disease phase specific medicament against chronic inflammatory diseases. Disease, cell-type, tissue and/or stage specific proteins and nucleic acids are identified with regard to the modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and auto-immune diseases is provided.

Abstract: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.